Consumer medicine information

Nufloxib

Norfloxacin

BRAND INFORMATION

Brand name

Nufloxib

Active ingredient

Norfloxacin

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Nufloxib.

What is in this leaflet

This leaflet answers some common questions about Nufloxib. It does not contain all the available information.

It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Nufloxib against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with your medicine. You may need to read it again.

What Nufloxib is used for

The name of your medicine is Nufloxib. It contains the active ingredient norfloxacin.

Nufloxib is an antibiotic that belongs to a group of medicines called quinolones. Nufloxib works by killing the bacteria that are causing your infection in different parts of the body.

Nufloxib is also used to treat;

  • Treat urinary tract infections
  • Treat gastrointestinal infections, in particular shigellosis and traveller's diarrhoea.

Nufloxib will not work against infections caused by viruses, such as colds or the flu.

Ask your doctor if you have any questions about why Nufloxib has been prescribed for you. Your doctor may have prescribed Nufloxib for another reason.

Nufloxib is not addictive.

This medicine is available only with a doctor's prescription.

Before you take Nufloxib

When you must not take Nufloxib

Do not take Nufloxib if you have an allergy to

  • other products containing norfloxacin (such as Noroxin, Norflohexal, nalidixic acid, Insensye)
  • any other quinolone antibiotic such as Avelox, C-Flox
  • any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include asthma, wheezing, shortness of breath, swelling of the face, lips or tongue, which may cause difficulty in swallowing or breathing. Symptoms may also include skin rash, itching, hives or joint pain.

Do not give Nufloxib to children or to growing teenagers (under the age of 18), unless advised by the doctor.

The safety and effectiveness of Nufloxib in children have not been established.

Do not take this medicine if you are pregnant or intend to become pregnant. It may affect your developing baby if you take it during pregnancy.

Do not take this medicine if you are breastfeeding or intend to breastfeed. The active ingredient in Nufloxib may pass into breast milk and may affect your baby.

Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking Nufloxib, talk to your doctor.

Before you start to take Nufloxib

Tell your doctor if you have any allergies to:

  • any other medicines
  • any other substances, such as foods, preservatives or dyes

Tell your doctor if you intend to become pregnant or intend to breastfeed. Nufloxib should not be used during pregnancy or while breast-feeding.

Tell your doctor if you have or have had any other health problems or medical conditions, including:

  • kidney disease
  • seizures or fits or a history of them
  • myasthenia gravis, a condition that affects the muscles
  • glucose-6-phosphate dehydrogenase deficiency
  • heart rhythm problems.
  • Arthropathy
  • Crystalluria
  • Vision disorders
  • Tendon inflammation
  • Diabetes
  • Risk of aortic aneurysm and dissection

If you have not told your doctor about any of the above, tell them before you take Nufloxib.

Taking other medicines

Tell your doctor if you are taking any other medicines, including any medicines that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with Nufloxib. These include:

  • theophylline (such as Nuelin), a medicine used to treat asthma
  • warfarin (such as Coumadin, Marevan), a medicine used to prevent blood clots
  • phenindione (such as Dindevan), a medicine also used to prevent blood clots
  • probenecid (Pro-Cid), a medicine used to treat gout
  • nitrofurantoin (Ralodantin, Macrodantin), a medicine used to treat urinary tract infections
  • ciclosporin (Neoral, Sandimmun, Cysporin), a medicine used to suppress the immune system
  • certain drugs that are metabolised by a specific enzyme: clozapine, ropinirole, tacrine, tizanidine
  • glibenclamide, a medicine used to treat diabetes
  • metronidazole (such as Flagyl, Metrogyl), a medicine used to treat various types of bacterial infections
  • non-steroidal anti-inflammatory drugs (NSAIDs), medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis
  • erythromycin, a medicine used to treat infections
  • cisapride, a medicine used to treat gastric reflux, usually experienced as heartburn
  • some medicines used to treat irregular heart beats such as sotalol, amiodarone, quinidine and procainamide
  • antipsychotics, medicines used to treat certain mental and emotional conditions
  • tricyclic antidepressants, medicines used to treat depression such as amitriptyline and nortriptyline.

These medicines may be affected by Nufloxib or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines.

Some medicines may interfere with the absorption of Nufloxib. These include:

  • iron or zinc supplements, and multivitamins containing them
  • calcium preparations
  • antacids (such as Mylanta, Alu-Tab, Gastrogel) used for indigestion
  • sucralfate (Ulcyte, Carafate), a medicine used to treat stomach ulcers
  • didanosine (Videx and Videx EC), a medicine used to treat HIV infections.

You can still take these medicines while you are taking Nufloxib; however, you must take Nufloxib at least 2 hours before or 2 hours after taking any of these medicines to make sure there is no problem with absorption.

Nufloxib may prolong the effect of coffee and other drinks containing caffeine.

Your doctor or pharmacist will be able to tell you what to do when taking Nufloxib with other medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking Nufloxib.

How to take Nufloxib

Follow all directions given to you by your doctor carefully. These directions may differ from the information contained in this leaflet.

If you do not understand the instructions on the pack, ask your doctor or pharmacist for help.

How much to take

Your doctor will tell you how many tablets you will need to take each day. This depends on your condition (for example if you have a kidney problem) and whether you are taking any other medicines.

The usual dose of Nufloxib is one 400 mg tablet morning and evening on an empty stomach.

The maximum total daily dose of Nufloxib should not exceed 800 mg per day.

How to take it

Swallow Nufloxib with a glass of water.

When to take it

Take Nufloxib on an empty stomach. For example, one hour before food or two hours after food. This will give the tablets a better chance of fighting the infection because food can interfere with the absorption of Nufloxib.

Do not take Nufloxib at the same time as taking iron or zinc supplements (or any multivitamins containing them), antacids, didanosine or sucralfate. Taking Nufloxib at the same time or even within two hours of taking these can interfere with the absorption of Nufloxib, so that the chance of Nufloxib fighting the infection won't be as good.

How long to take it

Continue taking Nufloxib until you finish the pack or until your doctor tells you to.

Do not stop taking your tablets because you are feeling better. If you do not complete the full course prescribed by your doctor, the infection may not clear completely, or your symptoms may return.

If you forget to take it

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Otherwise, take it as soon as you remember, and then go back to taking your tablets as you would normally.

Do not take a double dose to make up for the dose that you missed.

If you are not sure what to do, talk to your doctor or pharmacist.

If you have trouble remembering to take your tablets, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or Poisons Information Centre (telephone 13 11 26) or go to Accident and Emergency at your nearest hospital if you think that you or anyone else may have taken too much Nufloxib. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

While you are using Nufloxib

Things you must do

If you become pregnant while you are taking Nufloxib tell your doctor immediately.

Tell all the doctors, dentists and pharmacists who are treating you that you are taking Nufloxib.

If you get severe diarrhoea, tell your doctor or pharmacist immediately. Do this even if it occurs several weeks after Nufloxib has been stopped. Diarrhoea may mean that you have a serious condition affecting your bowel. You may need urgent medical care. Do not take any diarrhoea medicine without first checking with your doctor.

Drink plenty of water or fluids while taking Nufloxib. This will help to prevent crystals forming in the urine, which can cause kidney problems.

Protect your skin when you are in the sun, especially between 10 am and 3 pm. Nufloxib may cause your skin to be much more sensitive to sunlight than it is normally. This may cause a skin rash, itching, redness, or a severe sunburn.

If outdoors, wear protective clothing and use a 30+ sunscreen. If your skin does appear to be burning, stop taking Nufloxib and tell your doctor.

If the symptoms of your infection do not improve within a few days, or if they become worse, tell your doctor.

If you are about to start taking any new medicine, tell your doctor and pharmacist that you are taking Nufloxib.

Try not to consume large amounts of caffeine while you are taking Norfloxacin.

Norfloxacin may increase the chance of you getting side effects from caffeine, such as sleeplessness, anxiety, tremor, increased heartbeat and headache. Caffeine is contained within coffee, tea, cola and energy drinks.

Things you must not do

Do not stop taking your tablets because you are feeling better, unless advised by your doctor. If you do not complete the full course prescribed by your doctor, all of the bacteria causing your infection may not be killed. These bacteria may continue to grow and multiply so that your infection may not clear completely, or it may return.

Do not give Nufloxib to anyone else, even if they have the same condition as you.

Do not use Nufloxib to treat any other complaints unless your doctor tells you to.

Things to be careful of

Be careful driving or operating machinery until you know how Nufloxib affects you. Nufloxib may cause dizziness or light-headedness in some people. Make sure you know how you react to Nufloxib before you drive a car, operate machinery, or do anything else that could be dangerous if you are dizzy or light-headed. If you drink alcohol, dizziness or light-headedness may be worse.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Nufloxib.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Ask your doctor or pharmacist to answer any questions you may have.

While you are using Nufloxib

Tell your doctor if you notice any of the following and they worry you:

  • nausea, upset stomach, stomach pain
  • headache
  • dizziness
  • disturbances to vision
  • rash
  • tiredness, changes in sleep pattern
  • vaginal thrush - sore and itchy vagina or discharge.

These side effects are usually mild.

Tell your doctor immediately if you notice any of the following:

  • increased sensitivity of the skin to the sun, with symptoms of sunburn (redness, blistering or itching) happening more quickly than usual
  • confusion, depression, hallucinations
  • bleeding or bruising more easily than usual
  • signs of anaemia such as tiredness, being short of breath and looking pale
  • numbness or tingling in the fingers or toes
  • worsening of the symptoms of myasthenia gravis
  • decreased feeling or sensitivity, especially in the skin
  • changes in your hearing.

These are serious side effects. You may need urgent medical attention. Serious side effects are rare.

If any of the following happen, stop taking Nufloxib and tell your doctor immediately or go to Accident and Emergency at your nearest hospital:

  • severe abdominal cramps or stomach cramps
  • watery and severe diarrhoea, which may also be bloody
  • skin rash, itching or hives or peeling or blistering of the skin
  • asthma, wheezing or shortness of breath
  • swelling of the face, lips tongue or throat that may cause difficulty in swallowing or breathing
  • yellowing of the skin or eyes
  • frequent infections such as fever, severe chills, sore throat or mouth ulcers
  • sudden and severe pain or swelling of the muscles, joints or tendons
  • seizures, convulsions or fits
  • passing little or no urine, blood in the urine.

These are very serious side effects. You may need urgent medical attention or hospitalisation. These side effects are rare.

After finishing Nufloxib

Tell your doctor immediately if you notice any of the following side effects, particularly if they occur several weeks after stopping treatment with Nufloxib:

  • severe abdominal cramps or stomach cramps
  • watery and severe diarrhoea, which may also be bloody
  • fever, in combination with one or both of the above.

These are rare but serious side effects. You may have a serious condition affecting your bowel. You may need urgent medical attention. However, these side effects are rare.

Do not take any diarrhoea medicine without first checking with your doctor.

Other side effects not listed above may also occur in some patients. Tell your doctor if you notice anything that is making you feel unwell.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

After using Nufloxib

Storage

Keep your tablets in the pack until it is time to take them. If you take the tablets out of the pack, they may not keep well.

Keep Nufloxib in a cool dry place where the temperature stays below 25°C.

Do not store it or any other medicine in the bathroom or near a sink.

Do not leave it in the car or on a windowsill. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is good place to store medicines.

Disposal

If your doctor tells you to stop taking the tablets or the tablets have passed their expiry date, ask your pharmacist what to do with any tablets that are left over.

Product description

What it looks like

Nufloxib are white, oval, biconvex, film-coated tablets.

Each pack contains 14 tablets.

Ingredients

Active:

Each Nufloxib tablet contains 400 mg of the active ingredient norfloxacin.

Inactive ingredients:

Each Nufloxib tablet also contains:

  • microcrystalline cellulose
  • croscarmellose sodium
  • colloidal anhydrous silica
  • magnesium stearate
  • hypromellose
  • titanium dioxide
  • propylene glycol
  • lactose monohydrate
  • macrogol 4000
  • purified talc

Nufloxib does not contain gluten, sucrose, tartrazine or any other azo dyes. Nufloxib contains lactose.

Supplier

Nufloxib is supplied in Australia by:

Alphapharm Pty Limited
Level 1, 30 The Bond
30 - 34 Hickson Road
Millers Point NSW 2000
www.mylan.com.au

Registration number:
AUST R 149416

This leaflet was prepared in Mar 2020.

Nufloxib_cmi\Mar 2020/00

Published by MIMS May 2020

BRAND INFORMATION

Brand name

Nufloxib

Active ingredient

Norfloxacin

Schedule

S4

 

1 Name of Medicine

Norfloxacin.

6.7 Physicochemical Properties

Norfloxacin is freely soluble in glacial acetic acid, and very slightly soluble in ethanol, methanol and water. It has a melting point of approximately 221°C.
Norfloxacin, a fluoroquinolone, differs from quinolones by having a fluorine atom at the 6 position and a piperazine moiety at the 7 position. Examples of antibacterial drugs which are quinolones include nalidixic acid and cinoxacin.

Chemical structure.


Chemical name: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid.
Molecular Formula: C16H18FN3O3.
Molecular Weight: 319.34.

CAS number.

CAS Registry No: 70458-96-7.

2 Qualitative and Quantitative Composition

Norfloxacin is a white to pale yellow crystalline powder.
Each tablet of Nufloxib contains 400 mg of norfloxacin as the active ingredient.
Nufloxib also contains lactose monohydrate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Nufloxib tablets are white, oval, biconvex film coated tablets.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Synthetic antibacterial agent for oral administration; a fluoroquinolone.
Norfloxacin has in vitro activity against a broad spectrum of Gram negative and some Gram positive aerobic bacteria. Norfloxacin inhibits bacterial deoxyribonucleic acid synthesis and is bactericidal.
At the molecular level three specific events are attributed to norfloxacin in Escherichia coli cells:
1. inhibition of the ATP dependent DNA supercoiling reaction catalysed by DNA gyrase;
2. inhibition of the relaxation of supercoiled DNA;
3. promotion of double stranded DNA breakage.

Microbiology.

Resistance to norfloxacin due to spontaneous mutation in vitro is a rare occurrence (range: 10-9 to 10-12 cells). Resistance of the organism has developed during therapy with norfloxacin in less than 1% of patients treated. Organisms in which development of resistance is greatest are the following: Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter sp., Enterococci.
For this reason, when there is a lack of satisfactory clinical response, culture and susceptibility testing should be repeated.
Norfloxacin is active in vitro against the following organisms.

Bacteria found in urinary tract infections.

Aerobic bacteria.

Gram positive bacteria including Streptococcus faecalis (Enterococcus), Staphylococcus aureus, Staph. epidermidis, Staph. saprophyticus.
Gram negative bacteria including Citrobacter diversus, C. freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K. pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa.

Bacteria found in gastrointestinal infections.

Shigella, E. coli, Salmonella typhi.
In addition, norfloxacin is active against Neisseria gonorrhoeae.
Norfloxacin is not generally active against obligate anaerobes.
Nalidixic acid resistant organisms are generally susceptible to norfloxacin in vitro; however, these organisms may have higher minimum inhibitory concentrations (MIC) to norfloxacin than nalidixic acid susceptible strains. There is generally no cross resistance between norfloxacin and other classes of antibacterial agents. Therefore, norfloxacin often demonstrates activity against indicated organisms resistant to the aminoglycosides (including gentamicin), penicillins, cephalosporins, tetracyclines, macrolides and sulphonamides, including combinations of sulfamethoxazole and trimethoprim. Antagonism has been demonstrated in vitro between norfloxacin and nitrofurantoin.

Susceptibility tests.

Dilution or diffusion techniques, either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. NCCLS). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.
A report of 'susceptible' indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of 'intermediate' indicates that the result should be considered equivocal and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.
This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of 'resistant' indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Note.

The prevalence of resistance may vary geographically for selected species and local information on resistance is desirable, particularly when treating severe infections.
Quantitative methods that require measurement of zone diameters give precise estimates of bacterial susceptibility. One such procedure has been recommended for use with discs to test susceptibility of norfloxacin.
Reports from the laboratory giving results of the standard single disc susceptibility test with a 10 microgram norfloxacin disc should be interpreted according to the following criteria.
Susceptible organisms produce zones of 13 mm or greater, indicating that the test organism is likely to respond to therapy.
Resistant organisms produce zones of 12 mm or less, indicating that other therapy should be selected.
A bacterial isolate may be considered susceptible if the MIC value for norfloxacin is equal to or less than 16 microgram/mL. Organisms are considered resistant if the MIC is equal to or greater than 32 microgram/mL.
The standardised quality control procedure requires use of control organisms.
The 10 microgram norfloxacin disc should give the zone diameters listed in Table 1 for the quality control strains.
Dilution susceptibility tests should give MICs between the ranges listed in Table 2 for the quality control strains.
Based on urinary concentrations of norfloxacin achieved in man, breakpoint criteria have been established as listed in Table 3.
Norfloxacin susceptibility test results should not be used to predict susceptibility to other less potent quinolone antibacterial agents such as nalidixic acid.

Animal pharmacology.

Norfloxacin and related drugs have been shown to cause arthropathy in immature animals of most species tested (see Section 4.4 Special Warnings and Precautions for Use).
Crystalluria has occurred in laboratory animals tested with norfloxacin. In dogs, needle shaped drug crystals were seen in the urine at doses of 50 mg/kg/day. In rats, crystals were reported following doses of 200 mg/kg/day.
Embryolethality and slight maternotoxicity (vomiting and anorexia) were observed in cynomolgus monkeys at doses of 150 mg/kg/day or higher.
Ocular toxicity, seen with some related drugs, was not observed in any norfloxacin treated animals.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

In fasting healthy volunteers, approximately 30 to 40% of an oral dose of norfloxacin is absorbed. Absorption is rapid following single doses of 200 and 400 mg. At the respective doses, mean peak serum and plasma concentrations of 0.8 and 1.5 microgram/mL are attained approximately one hour after dosing. The presence of food may decrease absorption. The effective half-life of norfloxacin in serum and plasma is three to four hours. Steady-state concentrations of norfloxacin will be attained within two days of dosing.

Distribution.

The serum protein binding of norfloxacin is between 10 and 15%.

Metabolism.

Within 24 hours of drug administration, 26 to 32% of the administered dose is recovered in the urine as norfloxacin with an additional 5 to 8% being recovered in the urine as six metabolites of considerably less antimicrobial potency.

Excretion.

The absorbed norfloxacin is eliminated mainly through renal excretion. Renal excretion occurs by both glomerular filtration and tubular secretion as evidenced by the high rate of renal clearance (approximately 275 mL/minute). Within 24 hours of drug administration, 26 to 32% of the administered dose is recovered in the urine as norfloxacin with an additional 5 to 8% being recovered in the urine as six metabolites of considerably less antimicrobial potency. However, urinary recovery may occasionally be very low. Only a small percentage (less than 1%) of the dose is recovered thereafter.
Two to three hours after a single 400 mg dose, urinary concentrations of 200 microgram/mL or more are attained in the urine. In healthy volunteers, mean urinary concentrations of norfloxacin remain above 30 microgram/mL for approximately twelve hours following a 400 mg dose. The urinary pH may affect the solubility of norfloxacin. Norfloxacin is least soluble at urinary pH of 7.5 with solubility increasing at pHs above and below this value.
The disposition of norfloxacin in patients with creatinine clearance rates greater than 30 mL/minute/1.73 m2 is similar to that in healthy volunteers. In patients with creatinine clearance rates equal to or less than 30 mL/minute/1.73 m2, the renal elimination of norfloxacin decreases so that the effective serum half-life is 8.6 to 11.5 hours. In these patients, alteration of dosage is necessary (see Section 4.2 Dose and Method of Administration). Drug absorption appears unaffected by decreasing renal function.
In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), norfloxacin is eliminated more slowly because of their slightly decreased renal function. Drug absorption appears unaffected. The effective half-life of norfloxacin in these elderly subjects is four hours.
Faecal recovery accounts for another 30% of the administered dose. This represents the unabsorbed drug along with a small contribution through biliary excretion. After a single 400 mg dose of norfloxacin, mean antimicrobial activities equivalent to norfloxacin 278, 773 and 82 microgram/g of faeces were obtained at 12, 24 and 48 hours, respectively.

5.3 Preclinical Safety Data

Genotoxicity.

Norfloxacin was tested for mutagenic activity in a number of in vivo and in vitro tests. Norfloxacin had no mutagenic effect in the dominant lethal test in mice and did not cause chromosomal aberrations in hamsters or rats at 500 to 1,000 mg/kg/day. Norfloxacin had no mutagenic activity in vitro in the Ames microbial mutagen test and V-79 mammalian cell assay. Although norfloxacin was weakly positive in the Rec assay for DNA repair, all other mutagenic assays were negative including a more sensitive test (V-79).

Carcinogenicity.

Information is not available at present on the carcinogenic potential of norfloxacin.

4 Clinical Particulars

4.1 Therapeutic Indications

Treatment.

Nufloxib is indicated for treatment of adults with:
Complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms.
Gastrointestinal infections, in particular shigellosis and traveller's diarrhoea.

Note.

Specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants.
Consideration should be given to available official guidance on the appropriate use of antibacterial agents.

Suppression.

Nufloxib is indicated for the suppression, in adults, of chronic, recurrent urinary tract infection.

4.3 Contraindications

Hypersensitivity to any component of this product or any chemically related quinolone antibacterials.
Children (paediatric patients, adolescents (under the age of 18)).
Pregnancy (see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy).

4.4 Special Warnings and Precautions for Use

Fluoroquinolones, including Nufloxib, have been associated with disabling and persistent adverse reactions involving different body systems that have occurred together in the same patient. These include, but are not limited to, serious adverse reactions involving the nervous system (see Nervous system) and musculoskeletal system (see Effect on tendons).
Reserve fluoroquinolones for proven or suspected infections where alternative agents are ineffective or contraindicated.

Arthropathy.

The oral administration of single doses of norfloxacin 100 mg/kg caused lameness in immature dogs. Histological examination of the weight bearing joints of these dogs revealed permanent lesions of the cartilage. Related drugs (e.g. nalidixic acid and cinoxacin) also produced erosions of the cartilage in weight bearing joints and other signs of arthropathy in immature animals of various species.

Crystalluria.

Needle shaped crystals were found in the urine of some volunteers who received either placebo, norfloxacin 800 mg or norfloxacin 1,600 mg (at or twice the recommended daily dose, respectively) while participating in a double blind, crossover study comparing single doses of norfloxacin with placebo. While crystalluria is not expected to occur under usual conditions with a dosage regimen of 400 mg twice daily, as a precaution, the daily recommended dosage should not be exceeded, and the patient should drink sufficient fluids to ensure a proper state of hydration and adequate urinary output.

Antibiotic associated colitis.

Antibiotic associated pseudomembranous colitis has been reported with nearly all antibiotics, including norfloxacin. A toxin produced with Clostridium difficile appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases, appropriate therapy with a suitable oral antibacterial agent effective against Cl. difficile should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis, e.g. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used.

Dysglycaemia.

As with all fluoroquinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. sulfonylurea) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended.

Nervous system.

The effects of norfloxacin on brain function or on the electrical activity of the brain have not been tested. Convulsions have been reported rarely in patients receiving norfloxacin. As with other organic acids, norfloxacin should be used with caution in individuals with a history of convulsions or known factors that predispose to seizures.
Quinolones, including norfloxacin, may exacerbate the signs of myasthenia gravis and lead to life threatening weakness of the respiratory muscles. Caution should be exercised when using quinolones, including norfloxacin, in patients with myasthenia gravis (see Section 4.8 Adverse Effects (Undesirable Effects)).
Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoesthesias, dysesthesias, or weakness have been reported in patients receiving fluoroquinolones including norfloxacin. Norfloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness and/or weakness in order to prevent the development of an irreversible condition (see Section 4.8 Adverse Effects (Undesirable Effects)).

Psychiatric adverse reactions.

Fluoroquinolones, including norfloxacin have been associated with an increased risk of psychiatric adverse reactions including: toxic psychosis, psychotic reactions progressing to suicidal ideations/thoughts, hallucinations or paranoia; depression, or self-injurious behaviour such as attempted or completed suicide; anxiety, agitation, or nervousness; confusion, delirium, disorientation, or disturbances in attention; insomnia or nightmares; memory impairment. These reactions may occur following the first dose. Advise patients receiving norfloxacin to inform their healthcare provider immediately if these reactions occur, discontinue the drug and institute appropriate care.

Vision disorders.

If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see Section 4.8 Adverse Effects (Undesirable Effects)).

Photosensitivity.

Photosensitivity reactions have been observed in patients who are exposed to excessive sunlight while receiving some members of this drug class. Excessive sunlight should be avoided. Therapy should be discontinued if photosensitivity occurs.

Effect on tendons.

Tendon inflammation and rupture that required surgical repair or resulted in prolonged disability have been reported with fluoroquinolone therapy including norfloxacin. This risk is further increased in elderly patients and those treated concurrently with corticosteroids. Tendon rupture can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. Norfloxacin should be discontinued at the first sign of pain, swelling, inflammation, or rupture of a tendon. Patients are advised to inform their health professional, rest the affected limb(s) and refrain from exercise.

Haemolytic reactions.

Rarely, haemolytic reactions have been reported in patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin (see Section 4.8 Adverse Effects (Undesirable Effects)).

Cardiac disorders.

Some quinolones have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmias. During post marketing surveillance, extremely rare cases of torsades de pointes have been reported in patients taking norfloxacin. These reports generally involve patients who had other concurrent medical conditions and the relationship to norfloxacin has not yet been established. Among drugs known to cause prolongation of the QT interval, the risk of arrhythmias may be reduced by avoiding use in the presence of hypokalaemia, significant bradycardia, or concurrent treatment with class Ia or class III antiarrhythmic agents. Quinolones should also be used with caution in patients using cisapride, erythromycin, antipsychotics, tricyclic antidepressants or have any personal or family history of QTc prolongation.

Aortic aneurysm and dissection.

Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.
Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis).
In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.

Instructions to patients.

Patients should be advised to take norfloxacin one hour before or two hours after a meal. Patients should also be advised to drink fluids liberally and not to take antacids concomitantly or within two hours after dosing.

Use in renal impairment.

Nufloxib is suitable for the treatment of patients with renal impairment; however, since Nufloxib is primarily excreted by the kidney, urinary levels may be significantly compromised by severe renal dysfunction. Alteration in dosage regimen is necessary for patients with impaired renal function (see Section 4.2 Dose and Method of Administration).

Use in the elderly.

See Section 4.2 Dose and Method of Administration.

Paediatric use.

As with other quinolones, norfloxacin has been shown to cause arthropathy in immature animals. The safety of norfloxacin in children has not been adequately explored and therefore norfloxacin is not to be used in children less than 18 years of age (see Section 4.3 Contraindications).

Effects on laboratory tests.

See Section 4.8 Adverse Effects (Undesirable Effects); Section 5.1 Pharmacodynamic Properties.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonise the antibacterial effect of norfloxacin in the urinary tract.
Quinolones, including norfloxacin, have been shown in vitro to inhibit CYP1A2. Concomitant use with drugs metabolised by CYP1A2 (e.g. clozapine, ropinirole, tacrine, theophylline, tizanidine) may result in increased substrate drug concentrations when given in usual doses. Patients taking any of these drugs concomitantly with norfloxacin should be carefully monitored.
Some quinolones, including norfloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life that may lead to accumulation of caffeine in plasma when products containing caffeine are consumed while taking norfloxacin.
Elevated plasma levels of theophylline have been reported with concomitant quinolone use. There have been rare reports of theophylline related side effects in patients on concomitant therapy with norfloxacin and theophylline. Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
Elevated serum levels of ciclosporin have been reported with concomitant use with norfloxacin. Therefore, ciclosporin serum levels should be monitored and appropriate ciclosporin dosage adjustments made when these drugs are used concomitantly.
Quinolones, including norfloxacin, may enhance the effects of the oral anticoagulant warfarin or its derivatives (e.g. phenprocoumon, acenocoumarol) and phenindione or similar agents. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.
The concomitant administration of quinolones, including norfloxacin, with glibenclamide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycaemia. Therefore, monitoring of blood glucose is recommended when these agents are coadministered.
Multivitamins, calcium preparations, products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within two hours of, the administration of norfloxacin, because they may interfere with absorption, resulting in lower serum and urine levels of norfloxacin.
Videx (didanosine) chewable/ buffered tablets or the paediatric powder for oral solution should not be administered concomitantly with, or within two hours of, the administration of norfloxacin, because these products may interfere with absorption, resulting in lower serum and urine levels of norfloxacin.
Some quinolones, including norfloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life that may lead to accumulation of caffeine in plasma when products containing caffeine are consumed while taking norfloxacin.
The concomitant administration of a nonsteroidal anti-inflammatory drug (NSAID) with a quinolone, including norfloxacin, may increase the risk of CNS stimulation and convulsive seizures. Therefore, Nufloxib should be used with caution in individuals receiving NSAIDs concomitantly.
Animal data have shown that quinolones in combination with fenbufen can lead to convulsions. Therefore, concomitant administration of quinolones and fenbufen should be avoided.
Lowered bioavailability of mycophenolic acid was observed in healthy volunteers receiving combined treatment with norfloxacin and metronidazole.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Norfloxacin did not adversely affect the fertility of male and female mice at oral doses up to 500 mg/kg/day.
(Category B3)
Norfloxacin has been shown to produce embryonic loss in cynomolgus monkeys when given in doses of 150 mg/kg/day with peak plasma levels that are two to three times those obtained in humans. There has been no evidence of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at 100 to 800 mg/kg/day. There were no adequate and well controlled studies in pregnant women. Since norfloxacin, like other drugs in this class, causes arthropathy in immature animals, it should not be used in pregnant women (see Section 4.3 Contraindications).
 It is not known whether norfloxacin is excreted in human milk.
When a 200 mg dose of norfloxacin was administered to breastfeeding mothers, norfloxacin was not detected in human milk. However, because the dose studied was low, because other drugs in this class are secreted in human milk, and because of the potential for serious adverse effects from norfloxacin in breastfed infants, a decision should be made to discontinue breastfeeding or to discontinue the drug at least 24 to 48 hours before restarting breastfeeding, taking into account the importance of the drug to the mother.

4.8 Adverse Effects (Undesirable Effects)

In clinical trials, norfloxacin was generally well tolerated.
The incidence of subjects reporting drug related adverse experiences in clinical trials involving 1,127 subjects was 3.4%. However, the overall incidence was 10.7% and the figures below were calculated without reference to drug relationship. Most adverse effects occur within the first few days of therapy.
The most common adverse experiences (1 to 3%) were either gastrointestinal or neurological: nausea 2.8%, headache 2.7% and dizziness 1.8%.
Additional effects (0.3 to 1%) were: fatigue, rash, abdominal pain, dyspepsia, somnolence, depression, insomnia, constipation, flatulence and heartburn.
Less frequent effects included: dry mouth, diarrhoea, fever, vomiting, erythema, euphoria, anxiety, irritability, hallucinations, altered taste, vaginal swelling and tendonitis.
Visual disturbances have been reported with drugs in this class.
Abnormal laboratory values observed in these 1,127 subjects in clinical trials were eosinophilia 1.8%, elevation of ALT (SGPT) and AST (SGOT) 1.8%, increased alkaline phosphatase 1.4%, and decreased white blood cell or neutrophil count 1.2%. Those occurring less frequently included increased serum urea, serum creatinine and lactate dehydrogenase (LDH), and decreased haematocrit.

Post marketing.

The following additional adverse effects have been reported since the drug was marketed.

Hypersensitivity reactions.

These include anaphylaxis, angioedema, dyspnoea, vasculitis, urticaria, arthritis, myalgia, arthralgia, interstitial nephritis, drug rash with eosinophilia and systemic symptoms (DRESS syndrome).

Skin.

Photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, pruritus and leukocytoclastic vasculitis.

Central nervous system.

Confusion, paraesthesias, polyneuropathy including Guillain-Barre syndrome, hypoesthesia, psychic disturbances including psychotic reactions, convulsions, tremors and myoclonus.

Liver, gastrointestinal.

Pseudomembranous colitis, pancreatitis (rare), hepatitis, including jaundice and cholestatic jaundice, elevated liver function tests.

Musculoskeletal.

Tendinitis, tendon rupture, exacerbation of myasthenia gravis, elevated creatine kinase (CK), muscle spasms.

Haematological.

Agranulocytosis, thrombocytopenia, haemolytic anemia, sometimes associated with glucose-6-phosphate dehydrogenase deficiency.

Genitourinary.

Vaginal candidiasis.

Renal function.

Renal failure.

Metabolic.

Dysglycaemia.

Special senses.

Dysgeusia, visual disturbances, hearing loss.

Causal relationship unknown.

A definite causal relationship could not be established with regard to the following adverse effects: conjunctivitis, eye pain/irritation and asthenia. On very rare occasions, prolonged QTc interval and ventricular arrhythmia (including torsades de pointes), hypertonia, ataxia, dysarthria, dysphasia, haemophthalmia, nystagmus, periorbital erythema, and proteinuria have been reported.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.2 Dose and Method of Administration

Norfloxacin tablets should be taken one hour before or two hours after a meal with a glass of water. Patients receiving norfloxacin should be well hydrated. Multivitamins, calcium preparations, other products containing iron or zinc, antacids containing magnesium and aluminium, sucralfate or Videx (didanosine), chewable/ buffered tablets or the paediatric powder for oral solution, should not be taken within two hours of administration of norfloxacin (see Section 4.4 Special Warnings and Precautions for Use). Nufloxib tablets should not be halved.

Urinary tract infection.

Normal renal function.

The recommended dosage of norfloxacin for the treatment of urinary tract infection is 400 mg twice daily for seven to ten days.
For uncomplicated lower urinary tract infections, the recommended dosage is 400 mg twice daily for three days. In one study of uncomplicated lower urinary tract infections, treatment for seven days resulted in somewhat better eradication rates than treatment for three days.
For suppression in chronic, recurrent urinary tract infection, 400 mg twice daily may be administered for four to twelve weeks.
Maximum total daily dosage should not exceed 800 mg per day.

Impaired renal function.

Norfloxacin may be used for the treatment of urinary tract infections in patients with renal insufficiency. In patients with a creatinine clearance rate of 30 mL/minute/1.73 m2 or less, the recommended dosage is one 400 mg tablet once daily for the duration given above. At this dosage, the urinary concentration exceeds the MICs for most urinary pathogens susceptible to norfloxacin, even when the creatinine clearance is less than 10 mL/minute/1.73 m2. However, such patients should be observed carefully for adverse effects due to possible drug retention.
When only the serum creatinine level is available, the following formula (based on sex, weight and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.

Use in the elderly.

Elderly patients with a creatinine clearance of greater than 30 mL/minute/1.73 m2 should receive the dosages recommended under Normal renal function.
Elderly patients with a creatinine clearance of 30 mL/minute/1.73 m2 or less should receive 400 mg once daily as recommended under Impaired renal function.

Gastrointestinal infection (Shigellosis, traveller's diarrhoea).

The recommended dosage is 400 mg twice daily for five days.

4.7 Effects on Ability to Drive and Use Machines

Norfloxacin may cause dizziness or lightheadedness; therefore, patients should know how they react to norfloxacin before they operate a vehicle or machinery or engage in activities requiring mental alertness and coordination.

4.9 Overdose

The acute oral LD50 values in male and female mice and male and female rats were greater than 4 g/kg.

Treatment.

In the event of acute overdosage, the patient should be carefully observed and given symptomatic and supportive treatment. Adequate hydration must be maintained.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

7 Medicine Schedule (Poisons Standard)

S4.

6 Pharmaceutical Particulars

6.1 List of Excipients

Excipients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide, propylene glycol, lactose monohydrate, macrogol 4000, and purified talc. See Section 2 Qualitative and Quantitative Composition.

6.2 Incompatibilities

See Section 4.5 Interactions with Other Medicines and Other Forms of Interactions; Section 4.2 Dose and Method of Administration.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.

6.5 Nature and Contents of Container

Al/Al Blister packs of 14 and 6 tablets.
Not all pack sizes may be marketed.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

Summary Table of Changes